FDA Recalls Neostigmine Methylsulfate Injectable Due to Contamination Risk
Nephron Sterile Compounding Center is recalling one lot of Neostigmine Methylsulfate Injection due to potential cross-contamination from product carryover during manufacturing. The recall affects 13,500 vials distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of sterile injectable medication with potential cross-contamination. Although no illnesses have been reported, this is a risk-of-harm product where contamination could cause patient harm, meeting the rubric criterion for High severity.
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling Neostigmine Methylsulfate Injection, USP, 1 mg/mL in 3 mL unit-dose vials. The recall is due to potential cross-contamination from product carryover during manufacturing, which is a deviation from Good Manufacturing Practice (CGMP) requirements.
The affected lot is NE1057A, which expires 10/23/2022. A total of 13,500 vials were distributed nationwide in the United States. The product is a prescription medication supplied as a sterile injectable.
Those who may have received this product should verify the lot number and contact their healthcare provider or supplier for guidance regarding the recall.
The recalled product
- Product
- PF-Neostigmine Methylsulfate Injection, USP, 3 mg/3 mL (1 mg/mL), One 3 mL Unit-Dose Vial, packaged in 30 x 3 mL Sterile Unit-Dose Vials per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th Street Extension, West Columbia, SC 29172; NDC 69374-932-33
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Hazard
- cross-contamination
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: NE1057A
- Exp. 10/23/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27